Literature DB >> 10052755

Associations between amino acids in the evolution of HIV type 1 protease sequences under indinavir therapy.

A J Brown1, B T Korber, J H Condra.   

Abstract

Significant diversity exists in amino acid sequences encoding HIV-1 protease in individuals naive for protease inhibitors, which could influence the rate of evolution of resistance. High-level resistance to indinavir requires multiple substitutions among at least 11 amino acid sites, and no single substitution was observed in all of 29 resistant isolates obtained from patients on long-term indinavir monotherapy. We have analyzed the evolution of PR in these sequences. The divergence from the baseline amino acid sequence by week 24 was 4%, increasing more than 7% by week 60. The mean difference between sequences from different patients at baseline was 6% (3-9%), rising to 10% after 40 weeks (3-16%), although at all time points nonsynonymous substitutions were less frequent than synonymous nucleotide changes. Analysis of associations between variants at different amino acid sites using a mutual information statistic revealed four pairs of sites to be significantly associated. In three cases these associations included residue 82. Clusters of baseline and week 24 amino acid sequences identified by maximum parsimony did not correlate significantly with the IC95 to indinavir, although a weak correlation of baseline clusters with phenotype at the week 24 time point was suggested.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10052755     DOI: 10.1089/088922299311420

Source DB:  PubMed          Journal:  AIDS Res Hum Retroviruses        ISSN: 0889-2229            Impact factor:   2.205


  7 in total

1.  Molecular dynamics simulations of 14 HIV protease mutants in complexes with indinavir.

Authors:  Xianfeng Chen; Irene T Weber; Robert W Harrison
Journal:  J Mol Model       Date:  2004-09-28       Impact factor: 1.810

2.  Kinetic, stability, and structural changes in high-resolution crystal structures of HIV-1 protease with drug-resistant mutations L24I, I50V, and G73S.

Authors:  Fengling Liu; Peter I Boross; Yuan-Fang Wang; Jozsef Tozser; John M Louis; Robert W Harrison; Irene T Weber
Journal:  J Mol Biol       Date:  2005-10-21       Impact factor: 5.469

3.  Mutation patterns of the reverse transcriptase and protease genes in human immunodeficiency virus type 1-infected patients undergoing combination therapy: survey of 787 sequences.

Authors:  N Yahi; C Tamalet; C Tourrès; N Tivoli; F Ariasi; F Volot; J A Gastaut; H Gallais; J Moreau; J Fantini
Journal:  J Clin Microbiol       Date:  1999-12       Impact factor: 5.948

4.  Genetic determinants in HIV-1 Gag and Env V3 are related to viral response to combination antiretroviral therapy with a protease inhibitor.

Authors:  Sarah K Ho; Elena E Perez; Stephanie L Rose; Roxana M Coman; Amanda C Lowe; Wei Hou; Changxing Ma; Robert M Lawrence; Ben M Dunn; John W Sleasman; Maureen M Goodenow
Journal:  AIDS       Date:  2009-08-24       Impact factor: 4.177

5.  Drug-associated changes in amino acid residues in Gag p2, p7(NC), and p6(Gag)/p6(Pol) in human immunodeficiency virus type 1 (HIV-1) display a dominant effect on replicative fitness and drug response.

Authors:  Sarah K Ho; Roxana M Coman; Joshua C Bunger; Stephanie L Rose; Patricia O'Brien; Isabel Munoz; Ben M Dunn; John W Sleasman; Maureen M Goodenow
Journal:  Virology       Date:  2008-07-02       Impact factor: 3.616

6.  Analysis of natural sequence variation and covariation in human immunodeficiency virus type 1 integrase.

Authors:  Richard E Myers; Deenan Pillay
Journal:  J Virol       Date:  2008-07-02       Impact factor: 5.103

7.  Strong Selection Significantly Increases Epistatic Interactions in the Long-Term Evolution of a Protein.

Authors:  Aditi Gupta; Christoph Adami
Journal:  PLoS Genet       Date:  2016-03-30       Impact factor: 5.917

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.